Replies to post #874 on Revance Therapeutics Inc (RVNC)

[dewophile]

It would seem a bit at odds though if EQT were to license daxi for therapeutic indications while owning dysport - a competitor to daxi - for consmetic indications. IF EQT wants daxi for cosmetic to promote a long acting and short acting that probably wouldn't be ideal since there would be some conflict and daxi promotion might suffer.
So I'm having a hard time seeing them as a partner for revance unless they drop dysport

[LongRun8]

Buyout talk

I probably missed this along the way in the previous threads here or on the Biotech Values board, so forgive me if I'm asking repeated questions. 

Bear in mind, I know this is an exercise in conjecture, as Dew was merely positing that Nestle might have been a possible acquirer of RVNC in 2018. 

So here are my questions.  Why would Nestlé's soon-to-be-former stake in Galderma (via L'Oreal) have prevented Nestle from acquiring Revance last year?  Would it be an antitrust thing with respect to Dysport?  Nestle purchased L'Oreal's stake in Galderma in 2014, so it wasn't like that was new information if Revance and Nestle were in buyout talks.  Or was the lack of an RVNC buyout possibly more likely related to the fact that there was internal debate in Nestle as to whether they truly wanted to carry on with their skincare division vs. focusing more on their other product lines?

If Nestle completes the sale of its skincare division, would they then be a logical acquirer of Revance with antitrust concerns no longer being an issue?  OTOH, Nestle probably wouldn't want to go back into the skincare division after selling it away, right? Unless they had to sell Dysport's rights to acquire Daxi? Also, why would EQT Parterns be a potential buyer of RVNC if they also purchase Nestlé's skin care division? 

Similarly, are antitrust issues why people don't believe that Allergan would acquire Revance either? 

Thanks in advance